Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL

Inclusion criteria

• Age 18 years or older, both males and females are eligible;
• Histologically confirmed peripheral T-cell lymphoma (PTCL) including PTCL-NOS and TFHL that has relapsed or is refractory after at least one line of systemic therapy. The definitions are as follows:

Relapse: Patients who achieved a Complete Response (CR) in previous treatments and have new lesions at the original site or elsewhere; Refractory: Patients who did not achieve CR after adequate treatment. For nasal-type NK/T-cell lymphoma, previous treatments must have included a chemotherapy regimen containing asparaginase;

• Patients who have undergone prior hematopoietic stem cell transplantation are allowed;
• ECOG PS 0-2
• Life expectancy greater than 3 months.
• Adequate organ function
• Contraception during study
• Informed consented

Exclusion criteria

• Prior treatment with EZH2 inhibitors or EZH1/2 inhibitors before enrollment;
• Peripheral T-cell lymphoma of subtypes other than PTCL-NOS and TFHL;
• History of other primary invasive malignancies that have not been in remission or have been in remission for no more than 3 years;
• Central nervous system involvement (meningeal or parenchymal);
• Known hypersensitivity to any study drugs;
• Participation in another clinical trial of an investigational drug within 4 weeks prior to the start of the study.
• Pregnant or lactation
• Active infection.
• Diseases and medical history:

• Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers
• Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
• Has a history of psychoactive substance abuse that cannot be discontinued
• Has any severe and/or uncontrolled disease.
• Uncontrollable autoimmune disease,
• Not able to comply to the protocol for mental or other unknown reasons
• Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.